Physician profile
Michael Shapiro
NPI 1740381516
$4,275.51
in general payments reported to CMS, 2019-2025
38 companies · $234 in 2025
The $234 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,609 · 2020: $734 · 2021: $565 · 2022: $504 · 2023: $289 · 2024: $340 · 2025: $234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $793 · Grant: $70.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $793.20 |
| Grant | $70.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $779.12 | 2019-2025 | |
| Abbvie INC. | $681.67 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $538.53 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $259.55 | 2022-2024 | Sotyktu |
| Biofrontera INC. | $169.92 | 2019-2021 | |
| Leo Pharma INC. | $152.83 | 2022-2025 | Adbry |
| Lilly USA, LLC | $145.11 | 2019-2022 | |
| Genzyme Corporation | $137.54 | 2019-2025 | |
| Dermira, INC. | $118.16 | 2019-2020 | |
| Pfizer INC. | $110.23 | 2019-2022 | |
| Encore Dermatology INC. | $103.40 | 2019-2020 | |
| Cardiovascular Systems INC. | $92.57 | 2021 | |
| Strata Skin Sciences, INC. | $83.01 | 2019-2024 | Xtrac |
| Ucb, INC. | $79.20 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $77.68 | 2019 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $70.24 | 2019 | |
| Vyne Pharmaceuticals INC. | $52.95 | 2020 | |
| Organogenesis INC. | $50.60 | 2025 | Novachor, Puraply Wound Matrix |
| Tactile Systems Technology INC | $48.65 | 2023-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Electromed, INC. | $47.64 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.59 | 2019-2020 | |
| Arcutis Biotherapeutics, INC. | $41.58 | 2024 | Zoryve |
| Janssen Biotech, INC. | $38.52 | 2022 | |
| Incyte Corporation | $34.57 | 2022 | |
| Biowound Solutions, INC. | $31.29 | 2025 | Bio-Connekt |
| Genentech USA, INC. | $30.16 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $30.06 | 2019 | |
| Springworks Therapeutics, INC. | $28.12 | 2025 | Gomekli |
| Kyowa Kirin, INC. | $25.92 | 2023 | Poteligeo |
| Almirall LLC | $25.69 | 2019 | |
| Amgen INC. | $24.00 | 2019 | |
| Verrica Pharmaceuticals INC. | $21.80 | 2024 | Ycanth |
| Allergan, INC. | $19.09 | 2019 | |
| Epi Health, LLC | $18.92 | 2019 | |
| Medtronic, INC. | $18.36 | 2024 | Heli-Fx Endoanchor System |
| Angiodynamics, INC. | $16.92 | 2025 | Auryon Laser System 100-120 Vac |
| Acera Surgical, INC. | $12.55 | 2022 | |
| Galderma Laboratories, L.P. | $11.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Shapiro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.